Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA: Neoadjuvant Chemo-Immunotherapy for Locally Advanced Sinonasal Carcinoma
NCT07645846Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Aug 2028
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and ipilimumab in sinonasal carcinoma, sponsored by Sun Yat-sen University. Primary endpoint: Major Pathological Response Rate at 9 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
sinonasal carcinoma
Beyond the preview
Go deeper on NCT07645846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645846.